• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Kairos Pharma Ltd.

    5/15/25 3:19:39 PM ET
    $KAPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KAPA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Kairos Pharma, LTD.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    48301N104

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    48301N104


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,696,924.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,696,924.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,696,924.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    48301N104


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,696,924.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,696,924.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,696,924.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kairos Pharma, LTD.
    (b)Address of issuer's principal executive offices:

    2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    48301N104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,696,924.00
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,696,924.00

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,696,924.00 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:05/15/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:05/15/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $KAPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KAPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KAPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

      Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," and will be presented on June 2. John Yu, M.D., Kairos CEO commented, "We look forward to the opportunity to continue to share data regarding our platform assets at one of the most prestigious oncology meetings in the world. We believe that KROS 101 has the potential to help optimize cancer tr

      4/28/25 8:00:00 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kairos Pharma Ltd. Provides Letter to Stockholders

      Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: To our valued stockholders, As we reflect on the Company's progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds. We currently have two ongoing clinical trials for our lead drug, ENV105, which is being tested in patients with prostate cancer in a Phase 2 trial and is being tested in a Phase 1 trial for patients with a type of lung cancer (called EGFR-dependent non-small cell lung cancer). As part of these trials, we are also identifying and confirming biomarker

      4/24/25 8:00:00 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

      Kairos Pharma, Ltd. (NYSE:KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense ("DoD") is providing $876,000 to advance a strategy to identify patients that are starting to develop resistance at an early stage. The grant was awarded to identify biomarkers for the Company's clinical study to address the major challenge in achieving a lasting cure for lung cancer patients. The g

      4/17/25 8:00:00 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KAPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP of Research and Development Murali Ramachandran bought $318 worth of shares (200 units at $1.59), increasing direct ownership by 0.15% to 133,057 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      11/25/24 8:30:12 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Samuelson Doug bought $3,750 worth of shares (2,500 units at $1.50), increasing direct ownership by 4% to 60,796 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      11/25/24 6:03:39 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Yu John S bought $5,760 worth of shares (4,000 units at $1.44), increasing direct ownership by 0.07% to 5,341,837 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      11/21/24 9:53:44 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KAPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Singhvi Rahul claimed ownership of 30,120 shares (SEC Form 3)

      3 - Kairos Pharma, LTD. (0001962011) (Issuer)

      4/30/25 4:10:05 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Bhowmick Neil was granted 14,000 shares, increasing direct ownership by 1% to 1,139,983 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      4/7/25 8:30:18 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP of Research and Development Murali Ramachandran was granted 14,000 shares, increasing direct ownership by 11% to 147,057 units (SEC Form 4)

      4 - Kairos Pharma, LTD. (0001962011) (Issuer)

      2/24/25 6:52:11 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KAPA
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Kairos Pharma Ltd.

      DEFR14A - Kairos Pharma, LTD. (0001962011) (Filer)

      5/16/25 3:38:26 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Kairos Pharma Ltd.

      SCHEDULE 13G - Kairos Pharma, LTD. (0001962011) (Subject)

      5/15/25 3:19:39 PM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kairos Pharma Ltd.

      10-Q - Kairos Pharma, LTD. (0001962011) (Filer)

      5/14/25 6:34:20 AM ET
      $KAPA
      Biotechnology: Pharmaceutical Preparations
      Health Care